Canaccord Genuity Maintains Buy on Cytokinetics (CYTK)
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $74.13 --0%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 12
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 9 | New: 12
Join SI Premium – FREE
Canaccord Genuity maintained a Buy rating on Cytokinetics (NASDAQ: CYTK) and lowered its price target to $4.00 (from $6.00).
"We think CK357 (tirasemtiv) Ph1/2 proof-of-concept data in ALS shows unique if early efficacy potential. We also think partner Amgen is committed to developing omecamtiv for heart failure," said analyst Ritu Baral.
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Shares of Cytokinetics closed at $0.68 yesterday.
"We think CK357 (tirasemtiv) Ph1/2 proof-of-concept data in ALS shows unique if early efficacy potential. We also think partner Amgen is committed to developing omecamtiv for heart failure," said analyst Ritu Baral.
For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.
Shares of Cytokinetics closed at $0.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Jefferies Downgrades Aegis Vopak Terminals (AEGISVOP:IN) to Hold
- ICICI Securities Downgrades Manappuram Finance Ltd (MGFL:IN) to Hold (3)
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
